Carperitide

Base Information

• Chemical Name: Carperitide
• CAS No.: 89213-87-6
• Deprecated CAS: 86903-70-0
• Molecular Formula: C127H203N45O39S3
• Molecular Weight: 3080.48
• European Community (EC) Number: 686-482-9
• ChEMBL ID: CHEMBL2104386
• DSSTox Substance ID: DTXSID201346607
• NCI Thesaurus Code: C169829
• Mol file: 89213-87-6.mol

Synonyms:alpha-atrial natriuretic peptide, human;alpha-hANP;alpha-human atrial natriuretic peptide;atrial natriuretic peptide precusor A, human;carperitide;natriuretic peptide precursor A, human;NPPA protein, human

Chemical Property of Carperitide

Chemical Property:

• Refractive Index: 1.688
• PSA: 1479.28000
• Density: 1.55 g/cm³
• LogP: -2.10540
• XLogP3: -14.9
• Hydrogen Bond Donor Count: 53
• Hydrogen Bond Acceptor Count: 48
• Rotatable Bond Count: 75
• Exact Mass: 3079.4480502
• Heavy Atom Count: 214
• Complexity: 6940

Purity/Quality:

95% ^*data from raw suppliers

AtrialNatriureticFactor(1-28)(human,porcine) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
• Isomeric SMILES: CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
• Recent ClinicalTrials: Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
• Recent EU Clinical Trials: Pharmacokinetics of ANP, a diuretic hormone, in neonates undergoing surgery for congenital heart defects. A pilot study.
• Recent NIPH Clinical Trials: Selection of Nitrate or Carperitide in acute phase for prevention from Cardiovascular events in patients with acute heart failure.
• Description: Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by recombinant technology. It was introduced in Japan as a treatment for acute congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the elevated left ventricular end-diastolic pressure and the index of myocardial oxygen consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was effective in improving hemodynamics and symptoms in 60% of patients with acute CHF. Carperitide was reported to be well tolerated with no significant adverse effects clinically. A beneficial effect on hemodynamics has been reported in chronic heart failure patients. Carperitide is also in clinical trials for maintenance of blood pressure during surgical operations. Atrial natriuretic peptide (ANP) is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, inhibit renin secretion, and increase sodium excretion. Human ANP binds to ANP receptors on cultured vascular smooth muscle cells (VSMCs) with a Kd value of approximately 1-2 nM and increases cGMP levels in a dose-dependent manner. It relaxes potassium-induced contraction of isolated canine renal arterial strips when used at concentrations of 10 and 100 ng/ml and dilates renal arteries in anesthetized dogs when used at doses ranging from 10 to 100 ng/kg. In a rat model of heart failure following experimental autoimmune myocarditis, human ANP, via osmotic mini pump for 28 days, decreases cardiomyocyte size as well as the amount of cardiac fibrosis and left ventricular remodeling. ANP (1-28) (human) is a 28 amino acid peptide corresponding to the human protein sequence.
• Uses: Treatment of decompensated congestive heart failure.

Technology Process of Carperitide

There total 1 articles about Carperitide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 50.0%

atrial natriuretic peptide (91917-63-4) → human atrial natriuretic peptide (89213-87-6)

Guidance literature:

With methyl 6-(methoxythio)-5-nitronicotinate; In water; acetonitrile; at 20 ℃; for 24h; pH=6;

DOI:10.1002/chem.201700952

upstream raw materials:

atrial natriuretic peptide

Refernces

• 1、 -. "Selective disulfidation reagent using nitrogen-containing compound and method for producing disulfide-containing compound". Page/Page column 28-30. . Retrieved 2020/12/02.